Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
  1. Predictions
buy

Esperion Therapeutis.Inc. buy Cantor Fitzgerald

Esperion Therapeutis.Inc.
Start price
€2.41
17.12.24 / 50%
Target price
€7.61
17.12.25
Performance (%)
25.63%
End price
€3.02
18.12.25
Summary
This prediction ended on 18.12.25 with a price of €3.02. The prediction had a final performance of 25.63%. Cantor_Fitzgerald has a follow-up prediction for Esperion Therapeutis.Inc. where he still thinks Esperion Therapeutis.Inc. is a Buy. Cantor_Fitzgerald has 50% into this prediction

Esperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.

Performance without dividends (%)
Name 1w 1m 1y
Esperion Therapeutis.Inc. -11.771% -11.771% 49.193%
iShares Core DAX® -3,81 % -1,47 % 6,06 %
iShares Nasdaq 100 0,49 % 2,21 % 12,68 %
iShares Nikkei 225® -4,42 % 4,97 % 30,91 %
iShares S&P 500 0,25 % 1,23 % 9,37 %

Comments by Cantor_Fitzgerald for this prediction

In the thread Esperion Therapeutis.Inc. diskutieren
Prediction Buy
Perf. (%) 25.63%
Target price 7.613
Change
Ends at 17.12.25

Esperion Therapeutics, Inc. (NASDAQ: ESPR) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $8.00 price target on the stock.
Ratings data for ESPR provided by MarketBeat

Cantor Fitzgerald 
0
Report Share
17.12.24
In the thread Trading Esperion Therapeutis.Inc.
Prediction Buy
Perf. (%) 25.63%
Target price 7.613
Change
Ends at 17.12.25

Die von Cantor_Fitzgerald gewählte maximale Laufzeit wurde überschritten

Cantor Fitzgerald 
0
Report Share
18.12.25

Current prediction by Cantor_Fitzgerald for Esperion Therapeutis.Inc.

buy
Esperion Therapeutis.Inc.

Start price
Target price
Perf. (%)
€2.78
12.11.25
-
12.11.26
-11.81%
15:38

Cantor Fitzgerald 
12.11.25 50%